Dermata Therapeutics, Inc. (DRMAW)

0.0096 0.0000 (0.00%) At close: 04:00PM EDT

Dermata Therapeutics, Inc.

3525 Del Mar Heights Road
Suite 332
San Diego, CA 92130
United States
858 800 2543
https://www.dermatarx.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 8

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Gerald T. Proehl	Founder, President, CEO & Chairman	392k	N/A	1959
Mr. David F. Hale	Co-Founder & Lead Independent Director	73k	N/A	1949
Ms. Kyri K. Van Hoose CPA, M.B.A.	Senior VP & CFO	415.8k	N/A	1978
Dr. Christopher J. Nardo M.P.H., Ph.D.	Senior VP & Chief Development Officer	443.52k	N/A	1965
Mr. Sean Proehl	Senior Director of Legal & Business Development	N/A	N/A	N/A
Dr. Maria Bedoya Toro Munera M.B.A., Ph.D.	Senior Vice President of Regulatory Affairs & Quality Assurance	27.04k	N/A	1951

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Corporate Governance

Dermata Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.